We are looking forward to participating in Piper Sandler's 36th Annual Healthcare Conference in New York next week. https://lnkd.in/epRAxDgs
CereVasc
医疗设备制造业
Boston,Massachusetts 3,225 位关注者
A company focused on the development of novel, minimally invasive treatments for patients with neurological disease
关于我们
CereVasc, Inc. is developing the eShunt System for the treatment of patients with communicating hydrocephalus, one of the most common neurological conditions affecting both children and adults.
- 网站
-
https://www.cerevasc.com
CereVasc的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Boston,Massachusetts
- 类型
- 私人持股
地点
-
主要
100 1st Ave
Suite 403
US,Massachusetts,Boston,02129
CereVasc员工
动态
-
Congratulations to?Dr. Koji Ebersole and the University of Kansas Medical Center team on their first eShunt? System case in the US Pilot Study of the?CereVasc eShunt System in Normal Pressure Hydrocephalus IDE trial!
-
We’re excited to share that CereVasc has been nominated for the Emerging MedTech Company of the Year at the 12th Annual #NEVYs24! Thank you to the New England Venture Capital Association (NEVCA) for recognizing us. We can’t wait to join our fellow innovators in Tech, Tough Tech, Healthcare IT, Life Science, and MedTech and celebrate at the House of Blues on December 5th! #NEVCA #Innovation
-
Our team is thrilled to be participating in WFITN NEW YORK 2024! Thank you to Dr. Pedro Lylyk of ENERI - Dr. Pedro Lylyk and Dr. Adel Malek of Tufts Medical Center for engaging talks on innovation and the eShunt System. #WFITN24
-
Excited to share a new publication in the Journal of Molecular Therapy which highlights the eShunt?? Platform as a CNS gene therapy delivery method. Thanks to the teams at UMass Chan Medical School and Tufts Medical Center for your work on this study. "We're very excited about these promising preclinical results, which suggest that the eShunt System delivery approach could provide biopharmaceutical and biotechnology organizations with a minimally invasive method for delivering gene therapies directly to the cortex and brain." #bbb #CNS #drugdelivery #neurovascular #endovascular https://lnkd.in/eeKCGPm7
CereVasc Announces Journal of Molecular Therapy Publication Highlighting the eShunt? Platform as a CNS Gene Therapy Delivery Method
prnewswire.com
-
We are thrilled to announce enrollment of 50 patients in our pilot studies of the eShunt System in patients with NPH! https://lnkd.in/e6F4qW-D #NPH #HAM2024 #hydrocephalus
CereVasc Announces Enrollment of the 50th Patient in Pilot Studies of the eShunt? System for Normal Pressure Hydrocephalus
prnewswire.com
-
Thank you to Dr. Pedro Nicolás Lylyk of the ENERI - Dr. Pedro Lylyk team for your fantastic presentation of the One-Year Safety of the eShunt Implant at the 2024 edition of SIMI in Buenos Aires! #SIMI2024
-
Congratulations to?Dr. David Altschul and the Montefiore Health System team on their first eShunt? System case in the US Pilot Study of the?CereVasc eShunt System in Normal Pressure Hydrocephalus IDE trial!
-
Thank you to Dr. Ivan Lylyk of ENERI - Dr. Pedro Lylyk and Dr. Adel Malek for delivering exciting talks on the eShunt System at the European Society for Minimally Invasive Neurological Therapy Annual Meeting. Dr. Lylyk discussed "One Year Safety of the?eShunt? Implant for?the Treatment of Communicating?Hydrocephalus" Dr. Malek discussed "Pilot study CereVasc eShunt system in NPH" #esmint2024
-
We are excited to announce Breakthrough Device Designation for the eShunt?? System from the FDA! "It is estimated that more than 700,000 individuals in the US suffer from NPH with the vast majority going untreated. Consequently, we have seen strong interest among patients, caregivers, and clinicians in an endovascular treatment option to address this significant health challenge." #endovascular #NPH #hydrocephalus https://lnkd.in/g9vuQT6z
eShunt? System Receives FDA Breakthrough Device Designation
prnewswire.com